Details of the Drug

General Information of Drug (ID: DMBKO2W)

Drug Name
ATI-355
Synonyms Atinumab; Anti-Nogo-A mAbs, Novartis; Anti-Nogo-A monoclonal antibodies, Novartis; 11C7; 7B12
Indication
Disease Entry ICD 11 Status REF
Nerve injury ND56.4 Phase 1 [1]
Drug Type
Antibody
Cross-matching ID
TTD ID
D0M0WM

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Reticulon-4 (RTN4) TT7GXMU RTN4_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT00406016) Acute Safety, Tolerability, Feasibility and Pharmacokinetics of Intrath. Administered ATI355 in Patients With Acute SCI. U.S. National Institutes of Health.
2 Limiting multiple sclerosis related axonopathy by blocking Nogo receptor and CRMP-2 phosphorylation. Brain. 2012 June; 135(6): 1794-1818.